- Home
- GECC vs IKT Comparison
GECC vs IKT Comparison
Compare GECC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- IKT
- Stock Information
- Founded
- GECC 2016
- IKT 2008
- Country
- GECC United States
- IKT United States
- Employees
- GECC N/A
- IKT N/A
- Industry
- GECC Finance: Consumer Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- IKT Health Care
- Exchange
- GECC Nasdaq
- IKT Nasdaq
- Market Cap
- GECC 127.9M
- IKT 123.7M
- IPO Year
- GECC N/A
- IKT 2020
- Fundamental
- Price
- GECC $7.85
- IKT $1.45
- Analyst Decision
- GECC Strong Buy
- IKT Buy
- Analyst Count
- GECC 1
- IKT 2
- Target Price
- GECC $11.50
- IKT $8.00
- AVG Volume (30 Days)
- GECC 277.8K
- IKT 98.8K
- Earning Date
- GECC 10-30-2025
- IKT 11-13-2025
- Dividend Yield
- GECC 19.47%
- IKT N/A
- EPS Growth
- GECC 29.91
- IKT N/A
- EPS
- GECC 1.58
- IKT N/A
- Revenue
- GECC $47,638,000.00
- IKT N/A
- Revenue This Year
- GECC $30.29
- IKT N/A
- Revenue Next Year
- GECC N/A
- IKT N/A
- P/E Ratio
- GECC $4.96
- IKT N/A
- Revenue Growth
- GECC 29.12
- IKT N/A
- 52 Week Low
- GECC $7.18
- IKT $1.42
- 52 Week High
- GECC $11.46
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- GECC 35.63
- IKT 38.24
- Support Level
- GECC $7.50
- IKT $1.43
- Resistance Level
- GECC $7.99
- IKT $1.60
- Average True Range (ATR)
- GECC 0.23
- IKT 0.09
- MACD
- GECC 0.16
- IKT -0.01
- Stochastic Oscillator
- GECC 82.72
- IKT 8.33
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.